Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hematology
Biotech
Takeda's $300M bet on Protagonist's blood cancer drug pays off
Takeda’s $300 million bet on the hematology asset appears to have paid off as the drug reduced blood procedures in a phase 3 trial.
James Waldron
Mar 3, 2025 8:45am
AbbVie sues BeiGene over blood cancer drug trade secrets
Sep 11, 2024 10:17am
Gut enzymes could make universal donor blood possible
Apr 29, 2024 4:32pm
FDA hands de novo clearance to Scopio's bone marrow pathology AI
Apr 17, 2024 12:56pm
Human embryo model displays early blood cell production
Dec 13, 2023 2:01pm
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
